Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Rating) was the recipient of some unusual options trading activity on Monday. Investors acquired 2,724 put options on the company. This is an increase of approximately 505% compared to the typical daily volume of 450 put options.
Institutional Investors Weigh In On Akero Therapeutics
A number of institutional investors have recently modified their holdings of AKRO. Northern Trust Corp lifted its position in Akero Therapeutics by 1.1% during the fourth quarter. Northern Trust Corp now owns 249,774 shares of the company’s stock worth $5,283,000 after purchasing an additional 2,831 shares during the period. Dimensional Fund Advisors LP lifted its position in Akero Therapeutics by 20.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 252,265 shares of the company’s stock worth $5,336,000 after purchasing an additional 42,019 shares during the period. BNP Paribas Arbitrage SA lifted its holdings in shares of Akero Therapeutics by 18.7% in the fourth quarter. BNP Paribas Arbitrage SA now owns 5,696 shares of the company’s stock worth $120,000 after acquiring an additional 898 shares during the last quarter. Citigroup Inc. lifted its holdings in shares of Akero Therapeutics by 59.3% in the fourth quarter. Citigroup Inc. now owns 49,844 shares of the company’s stock worth $1,054,000 after acquiring an additional 18,563 shares during the last quarter. Finally, Rafferty Asset Management LLC lifted its holdings in shares of Akero Therapeutics by 33.6% in the fourth quarter. Rafferty Asset Management LLC now owns 56,159 shares of the company’s stock worth $1,188,000 after acquiring an additional 14,135 shares during the last quarter.
Akero Therapeutics Stock Performance
Shares of AKRO opened at $12.27 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.90 and a current ratio of 6.90. Akero Therapeutics has a twelve month low of $7.52 and a twelve month high of $26.98. The firm has a market cap of $461.00 million, a P/E ratio of -3.91 and a beta of 0.56. The firm’s 50 day moving average price is $11.85 and its two-hundred day moving average price is $11.80.
About Akero Therapeutics
Akero Therapeutics, Inc, a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body.
- Get a free copy of the StockNews.com research report on Akero Therapeutics (AKRO)
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn’t Differentiate, But it’s Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.